Catalyst Pharmaceuticals shares decline 2.59% after-hour due to Hoth Therapeutics' clinical trial expansion for cancer patients.

Catalyst Pharmaceuticals, Inc. experienced a decline of 2.59% in after-hours trading. The stock fell in response to news that Hoth Therapeutics expanded its clinical trial for cancer patients, specifically focusing on treating skin toxicities related to EGFR inhibitors. This development, while targeted at a different therapeutic area, might have raised concerns among investors about the company's focus and potential dilution of resources, leading to the negative after-hours price movement. The addition of Dr. Marlowe to NewHydrogen's development team, although unrelated to Catalyst Pharmaceuticals, does not seem to be a driving factor for the stock's decline.